Is Ketorolac Nasal Spray the Up and Coming Acute Pain Reliever?

Is Ketorolac Nasal Spray the Up and Coming Acute Pain Reliever?

Ketorolac TromethamineWhat if patients with acute pain could utilize a nasal spray to ease their discomfort? That is exactly what can be done when patients are given Ketorolac Tromethamine CAS# 74103-06-3. Known as the brand name Sprix, this intranasal solution for acute pain is not only novel, it is also proving to be efficacious. Some distinct advantages of Ketorolac nasal spray are that is has fewer side effects when compared to opioids, it is non-addictive and the administration is quick and painless. As a prescription intranasal formula of Ketorolac, which is an analgesic non-steroidal anti-inflammatory drug {NSAID}, this form of dosing is perfect for patients who have difficulty swallowing pills or who do not want a painful injection. The patent for this formulation of Ketorolac expires for Roxro Pharmaceuticals on Dec. 25, 2018, paving the way for additional generic forms of this pain medication to prosper.

ketorolac tromethamineKetorolac Tromethamine is regularly administered non-narcotic injectable analgesic in many U.S. hospitals. Patients with moderate to severe pain can benefit from this effectual medication, and the option of a simple to manipulate intranasal spray is advantageous to patients and practitioners.  Sprix was approved by the FDA on May 17, 2010, and studies have been and are currently still being conducted. Studies of Ketorolac {Sprix} have revealed extremely positive findings, such as the fact that plasma concentration of Sprix is reached in just thirty minutes for many patients. In addition, the use of intranasal Ketorolac has proven to reduce the amount of morphine patients need by between 26% and 34%. Patients’ surveys have rated Ketorolac Nasal Spray as being good to excellent as well, in post-use surveys. The side effects of Sprix are mild, and may include slight nasal irritation. Many patients who have been prescribed this pain relieving nasal spray have touted the ease of availability through self-administration, as compared to the injections which need to be administered onsite.

LGM Pharma provides API Ketorolac Tromethamine for research and development purposes. Clients can be assured of continuous support throughout the R&D process, as well as quality API products.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service